Raúl Perea Amarillo

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

Federico Argüelles‐Arias, María Fernanda Guerra Veloz, Raúl Perea Amarillo et al. · Digestive Diseases and Sciences · 2017 · 44 citations · Full text

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results

Federico Argüelles‐Arias, María Fernanda Guerra Veloz, Raúl Perea Amarillo et al. · European Journal of Gastroenterology & Hepatology · 2017 · 42 citations · Full text

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

María Fernanda Guerra Veloz, Juan María Vázquez Morón, María Belvis Jiménez et al. · Revista Española de Enfermedades Digestivas · 2018 · 18 citations · Full text

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdés Delgado et al. · Therapeutic Advances in Gastroenterology · 2019 · 18 citations · Full text

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

María Fernanda Guerra Veloz, Federico Argüelles‐Arias, Luisa Castro Laria et al. · World Journal of Gastroenterology · 2018 · 17 citations · Full text